photo

Wu Lab

We are in the process of identifying molecular and genetic changes of urologic cancers that correlate with the cancer disease behaviors, both clinically and pathologically. The long-term goal of these studies is to develop new diagnostic methods and therapeutic regiments for these cancers.

Chin-Lee Wu, PhD, MD

Associate Pathologist
Massachusetts General Hospital

Associate Professor of Pathology
Harvard Medical School

Research Interests

We are in the process of identifying molecular and genetic changes of urologic cancers that correlate with the cancer disease behaviors, both clinically and pathologically. The long-term goal of these studies is to develop new diagnostic methods and therapeutic regiments for these cancers.

Prostate cancer is the most common cancer and the second leading cause of cancer death of men in the US. We are interested in identifying the genes or gene expression profiles associated with the development, diagnosis and prognosis of prostate cancer. We use laser capture micro dissection and DNA microarray to approach this issue. The gene expression profiles will be used to better predict the disease outcome and guide treatment decision. The genes identified by this approach may also be used for new therapeutic targets. Most prostate cancer death is due to the development of androgen independence. Androgen receptor is responsible for cell growth in both androgen dependent and independent prostate cancers. We are studying two novel androgen receptor co-activators that may be involved in the development of androgen independence in prostate cancer. Characterizing these androgen receptor co-activators may lead to new drug targets for androgen independent prostate cancer.

Bladder cancer is responsible for more than 130,000 deaths annually worldwide and is the fifth most common solid malignancy in the United States. The overall 5-year survival of muscle invasive bladder cancer is 50%. We are studying new treatment modality that is based on targeting specific oncogene product in bladder cancer. The new molecular treatment method blocks signal transduction pathway and suppresses cancer cell proliferation.

Kidney cancer is difficult to screen and detect in its early stage when surgical treatment is most effective. We are studying serum and tissue markers that can be used in screening and diagnosis of this cancer.

Our laboratory, supported by Urology, Pathology and the MGH Cancer Center, enjoys extensive collaborations with other members of the researcher community both locally or around the World. We often provide clinical, research and technical expertise as well as pathology specimens to these collaborative studies.

Wu Laboratory

Massachusetts General Hospital
Urology Research Laboratory
55 Fruit Street
Boston, MA 02114

Phone: 617-724-1420
Fax: 617-724-7803


Email: cwu2@partners.org